Congenital Myasthenic Syndromes in Adult Neurology Clinic
Neurol 91:e1770-e1777, Kao, J.C.,et al, 2018
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Dysphagia as the Sole Manisfestation of Myasthenia Gravis
JNNP 76:1297-1300, Llabrs,M.,et al, 2005
Are MuSK Antibodies the Primary Cause of Myasthenic Symptoms?
Neurol 62:1945-1950,1920, Selcen,D.,et al, 2004
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Seronegative Lambert-Eaton Myasthenic Syndrome
Neurol 59:1773-1775, Nakao,Y.K.,et al, 2002
Myasthenic Symptoms in Patients with Mitochondrial Myopathies
Muscle & Nerve 18:1338-1340995., Forestier,N.L.,et al, 1995
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Congenital Myasthenic Syndromes
In:Neurologic Clinics, 12:401-4371994., Engel,A.G., 1994
Race, Sex, and Puberty Influence Onset, Severity, and Outcome in Juvenile Myasthenia Gravis
Neurol 44:1208-1214, Andrews,P.I.,et al, 1994
Acetylcholine Receptor Antibodies in Juvenile Myasthenia Gravis
Neurol 43:977-982, Andrews,P.I.,et al, 1993
Seronegative Generalized Myasthenia Gravis:Low Frequency of Thymic Pathology
Neurol 42:586-589, Verma,P.K.&Oger,J-F., 1992
Seronegative Myasthenia Gravis
Neurol 38:514-517, Soliven,B.C.,et al, 1988
Myasthenia Gravis without Acetylcholine-Receptor Antibody:A Distinct Disease Entity
Lancet 1:116-118, Mossman,S.,et al, 1986
Addressing Systemic Complications of Acute Stroke: A Scientific Statement From the American Heart Association
Stroke 56:e15-e29, Kumar,S.,et al, 2025
The "Chameleon Eyes Sign" in Myasthenia Gravis
Neurol 103:e209756, Zara,P.,et al, 2024
Ocular Myasthenia Gravis, Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator
Neurol 102:e209260, Young,A. & Johnston,J.L., 2024
Clinicopathologic Conference, Myasthenia Gravis
NEJM 391:1441-1450, Case 32-2024, 2024
Clinicopathologic Conference, Brain Abscess Due to Infection with Listeria Monocytogeneses
NEJM 391:1529-1538, Case 33-2024, 2024
Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology
Ann Neurol 96:1020-1025, Falso,S.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Curtain Sign
NEJM 387:e7, Sherman, S.V., 2022
A 68-Year-Old Man with Proximal Weakness and Seizures
Neurol 97:e423-e428, Chen, T., 2021
Myasthenia Grais
www.mda.org, , 2021
A 71-Year-Old Man Presenting with Acute Onset Dysarthria and Dysphagia
Neurol 96:180-184, Spagni, G.,et al, 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Acetylcholine Receptor-Antibody-Positive Myasthenia Gravis Presenting with Early Atrophy and Nonfluctuating Weakness of Proximal Limb Muscles
J Clin Neurol 16:714-716, Pancheri, E.,et al, 2020
Myasthenic Crisis Demanding Mechanical Ventilation
Neurol 94:e299-e313, Neumann, B.,et al, 2020
Long-Term Follow-Up, Quality of Life, and Survival of Patients with Lambert-Eaton Myasthenic Syndrome
Neurol 94:e511-e520, Lipka, A.F.,et al, 2020
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Useful Bedside Testing for Myasthenia Gravis
Neurol 94:e1870-e1871, Gomes del Carvalho Neto, E.,et al, 2020
Thymectomy for Myasthenia Gravis
Neurol 94:705-709, Gronseth, G.S.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
The Face of Myasthenia Gravis
Neurol 95:89-90, Ruiter, A.M.,et al, 2020
Ptosis that Resolves with Application of an Ice Pack
BMJ 369:m1147, Chakraborty, A. & Jacob, J., 2020
Drug Approved for Rare Muscle Weakening Syndrome
JAMA 321:239, Voelker, R., 2019
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Bilateral Cavernous Carotid Aneurysms: Atypical Presentation of a Rare Cause of Mass Effect
Front Neurol doi:10.3389/fneur.2018.0069, Gagliardi, D.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
A Child with Arthrogryposis
Neurol 91:e995-e998, Irumudomom, O. & Ghosh, P.S., 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017